Emotional and cognitive changes in chronic kidney disease.

Szczegóły
Abstrakt

Tytuł:: Emotional and cognitive changes in chronic kidney disease.
Autorzy:: Kim DS; Department of Anatomy, Soonchunhyang University College of Medicine, Cheonan, Korea.
Kim SW; Graduate School of New Drug Discovery & Development, Chungnam National University, Daejeon, Korea.
Gil HW; Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
Źródło:: The Korean journal of internal medicine [Korean J Intern Med] 2022 May; Vol. 37 (3), pp. 489-501. Date of Electronic Publication: 2022 Mar 08.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [Seoul] : Korean Association of Internal Medicine
MeSH Terms:: Cerebrovascular Disorders*
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/diagnosis
Renal Insufficiency, Chronic*/drug therapy
Uremia*/therapy
Cognition ; Female ; Humans ; Indican ; Male
References:: J Neurosci. 2015 Feb 4;35(5):1892-904. (PMID: 25653350)
BMC Nephrol. 2015 Sep 21;16:155. (PMID: 26390864)
Korean J Intern Med. 2020 Nov;35(6):1305-1316. (PMID: 32872729)
Mol Psychiatry. 2008 Jul;13(7):661-72. (PMID: 17667964)
Sci Rep. 2019 Feb 28;9(1):3097. (PMID: 30816118)
J Int Neuropsychol Soc. 2019 Jan;25(1):101-114. (PMID: 30463631)
Clin Interv Aging. 2017 Sep 08;12:1419-1428. (PMID: 28932108)
J Psychiatry Neurosci. 2015 Mar;40(2):78-88. (PMID: 25268789)
J Ren Nutr. 2010 Sep;20(5 Suppl):S2-6. (PMID: 20797565)
J Alzheimers Dis. 2018;65(3):897-915. (PMID: 30103322)
Nat Neurosci. 2014 Jan;17(1):106-13. (PMID: 24241397)
Pain. 1998 Nov;78(2):79-98. (PMID: 9839818)
Kidney Int. 2020 Mar;97(3):466-476. (PMID: 32001065)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
Int Urol Nephrol. 2016 May;48(5):807-15. (PMID: 26861060)
Psychiatry Clin Neurosci. 2008 Oct;62(5):554-61. (PMID: 18950375)
Physiol Behav. 1987;40(6):793-7. (PMID: 3313453)
Exp Neurol. 2012 Jul;236(1):28-33. (PMID: 22510484)
J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7. (PMID: 16291918)
Metab Brain Dis. 2016 Aug;31(4):929-36. (PMID: 27167984)
Hemodial Int. 2018 Apr;22(2):150-160. (PMID: 28799704)
Physiol Behav. 2015 Aug 1;147:324-33. (PMID: 25980628)
Am J Kidney Dis. 2009 Sep;54(3):433-9. (PMID: 19493600)
J Am Soc Nephrol. 2013 Feb;24(3):353-63. (PMID: 23291474)
BMC Med. 2016 Dec 14;14(1):206. (PMID: 27964726)
Nephrology (Carlton). 2020 Aug;25(8):625-633. (PMID: 32133699)
Nephrol Dial Transplant. 2006 Nov;21(11):3275-82. (PMID: 16861731)
Toxins (Basel). 2014 Jan 03;6(1):180-93. (PMID: 24394639)
J Neuropsychiatry Clin Neurosci. 2018 Fall;30(4):310-317. (PMID: 30045680)
J Neurosci. 2009 Dec 9;29(49):15375-85. (PMID: 20007462)
Stroke. 2007 Dec;38(12):3121-6. (PMID: 17962588)
Neurosci Biobehav Rev. 2015 Apr;51:138-50. (PMID: 25636946)
Behav Pharmacol. 2015 Sep;26(6):616-26. (PMID: 26221833)
Am J Kidney Dis. 2009 Mar;53(3):438-47. (PMID: 19070412)
Nature. 2012 Jun 13;486(7402):261-5. (PMID: 22699620)
Br J Health Psychol. 2015 May;20(2):374-95. (PMID: 24811542)
Kidney Res Clin Pract. 2021 Mar;40(1):99-108. (PMID: 33789385)
J Gerontol A Biol Sci Med Sci. 2018 Mar 2;73(3):393-399. (PMID: 29244090)
Korean J Intern Med. 2021 Jan;36(1):106-113. (PMID: 31311261)
Brain Res Brain Res Rev. 2001 Aug;36(1):60-90. (PMID: 11516773)
Brain Sci. 2021 Jun 30;11(7):. (PMID: 34209259)
Genes Brain Behav. 2008 Feb;7(1):120-8. (PMID: 17696993)
Dialogues Clin Neurosci. 2011;13(1):7-23. (PMID: 21485743)
Neuron. 2016 Feb 17;89(4):857-66. (PMID: 26853301)
Am J Kidney Dis. 2005 Nov;46(5):919-24. (PMID: 16253733)
Sci Rep. 2020 Jun 11;10(1):9483. (PMID: 32528183)
Nature. 2018 Feb 14;554(7692):317-322. (PMID: 29446381)
Alzheimers Res Ther. 2019 Apr 9;11(1):31. (PMID: 30967155)
Korean J Intern Med. 2021 Jul;36(4):753-766. (PMID: 34237822)
J Am Geriatr Soc. 2010 Feb;58(2):338-45. (PMID: 20374407)
Kidney Res Clin Pract. 2020 Dec 31;39(4):387-401. (PMID: 33184238)
Neuron. 2010 Jan 28;65(2):257-69. (PMID: 20152131)
Nat Rev Nephrol. 2020 Aug;16(8):452-469. (PMID: 32235904)
Neurology. 2006 Jul 25;67(2):224-8. (PMID: 16864812)
Neuron. 2021 May 5;109(9):1497-1512.e6. (PMID: 33823138)
Kidney Res Clin Pract. 2021 Mar;40(1):12-28. (PMID: 33789382)
Nature. 2018 Feb 14;554(7692):323-327. (PMID: 29446379)
Naunyn Schmiedebergs Arch Pharmacol. 2019 Jan;392(1):1-18. (PMID: 30470917)
BMJ Open. 2018 Dec 4;8(12):e023520. (PMID: 30518585)
J Ren Care. 2022 Jun;48(2):93-101. (PMID: 34227741)
Eur Radiol. 2019 Mar;29(3):1415-1424. (PMID: 30105409)
J Alzheimers Dis Rep. 2021 Feb 24;5(1):121-133. (PMID: 33782665)
Kidney Int. 2013 Jul;84(1):179-91. (PMID: 23486521)
Hippocampus. 2008;18(8):824-34. (PMID: 18493969)
BMJ. 2010 Jul 26;341:c3666. (PMID: 20660506)
Gen Hosp Psychiatry. 2021 Mar-Apr;69:27-40. (PMID: 33516963)
Kidney Int. 2004 Mar;65(3):1009-16. (PMID: 14871421)
Sci Adv. 2019 Mar 20;5(3):eaav0316. (PMID: 30906861)
Nat Commun. 2015 Dec 08;6:8997. (PMID: 26646366)
Front Genet. 2014 Apr 23;5:88. (PMID: 24795750)
Semin Dial. 2012 Jul;25(4):428-38. (PMID: 22809005)
Front Pharmacol. 2017 Jun 12;8:370. (PMID: 28659803)
Adv Chronic Kidney Dis. 2007 Jan;14(1):82-99. (PMID: 17200048)
Int J Mol Sci. 2019 Jan 31;20(3):. (PMID: 30708974)
Am J Kidney Dis. 2020 Nov;76(5):679-689. (PMID: 32492463)
Kidney Res Clin Pract. 2021 Mar;40(1):109-119. (PMID: 33706479)
Nephrology (Carlton). 2019 Jan;24(1):50-55. (PMID: 28949427)
Neurotoxicology. 2014 Sep;44:184-93. (PMID: 25003961)
Int J Nephrol Renovasc Dis. 2018 Mar 12;11:93-102. (PMID: 29559806)
J Korean Med Sci. 2016 Jun;31(6):915-23. (PMID: 27247501)
J Am Soc Nephrol. 2015 Apr;26(4):876-87. (PMID: 25145928)
Pol J Pharmacol. 2001 May-Jun;53(3):263-9. (PMID: 11785927)
Lancet. 2010 Apr 10;375(9722):1287-95. (PMID: 20382325)
J Am Soc Nephrol. 2020 Jul;31(7):1509-1521. (PMID: 32527975)
Kidney Int. 2011 Jan;79(1):14-22. (PMID: 20861818)
Contrib Nephrol. 2018;196:27-36. (PMID: 30041201)
Expert Opin Ther Pat. 2014 Jan;24(1):29-46. (PMID: 24094047)
J Clin Med. 2019 Feb 05;8(2):. (PMID: 30764571)
Front Med (Lausanne). 2020 Jan 09;6:311. (PMID: 31998731)
Exp Biol Med (Maywood). 2011 Jan;236(1):107-12. (PMID: 21239740)
Radiology. 2018 Sep;288(3):849-858. (PMID: 29893643)
Can J Psychiatry. 2004 Feb;49(2):124-38. (PMID: 15065747)
Kidney Int. 2006 May;69(9):1662-8. (PMID: 16598203)
J Am Med Dir Assoc. 2015 Apr;16(4):349.e1-5. (PMID: 25669668)
Hum Mol Genet. 2011 Aug 1;20(15):3093-108. (PMID: 21558424)
Life Sci. 2016 Sep 15;161:27-36. (PMID: 27493078)
Kidney Res Clin Pract. 2014 Sep;33(3):132-8. (PMID: 26877964)
Nat Med. 2014 Aug;20(8):886-96. (PMID: 24973918)
Physiol Behav. 2015 Jan;138:133-40. (PMID: 25447335)
Contributed Indexing:: Keywords: Brain; Cognitive dysfunction; Depressive disorder; Kidney failure, chronic; Uremia
Substance Nomenclature:: N187WK1Y1J (Indican)
Entry Date(s):: Date Created: 20220307 Date Completed: 20220506 Latest Revision: 20220716
Update Code:: 20240105
PubMed Central ID:: PMC9082446
DOI:: 10.3904/kjim.2021.492
PMID:: 35249316
: Czasopismo naukowe

Full Text Finder

Chronic kidney disease (CKD) leads to cognitive impairment and emotional changes. However, the precise mechanism underlying the crosstalk between the kidneys and the nervous system is not fully understood. Inflammation and cerebrovascular disease can influence the development of depression in CKD. CKD is one of the strongest risk factors for cognitive impairment. Moreover, cognitive impairment occurs in CKD as patients experience the dysregulation of several brain functional domains due to damage caused to multiple cortical regions and to subcortical modulatory neurons. The differences in structural brain changes between CKD and non-CKD dementia may be attributable to the different mechanisms that occur in CKD. The kidney and brain have similar anatomical vascular systems, which may be susceptible to traditional risk factors. Vascular factors are assumed to be involved in the development of cognitive impairment in patients with CKD. Vascular injury induces white matter lesions, silent infarction, and microbleeds. Uremic toxins may also be directly related to cognitive impairment in CKD. Many uremic toxins, such as indoxyl sulfate, are likely to have an impact on the central nervous system. Further studies are required to identify therapeutic targets to prevent changes in the brain in patients with CKD.

Informacja